General information about company
Scrip code*		540204
NSE Symbol*		NOTLISTED
MSEI Symbol*		NOTLISTED
ISIN*		INE666Q01016
Name of company		Eiko Lifesciences Ltd
Type of company		Main Board
Class of security		Equity
Date of start of financial year		01-04-2025
Date of end of financial year		31-03-2026
Date of board meeting when results were approved		29-07-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange		24-07-2025
Description of presentation currency		INR
Level of rounding		Lakhs
Reporting Type		Quarterly
Reporting Quarter		First quarter
Nature of report standalone or consolidated		Consolidated
Whether results are audited or unaudited for the quarter ended		Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting		Multi segment
Description of single segment
Start date and time of board meeting		29-07-2025 18:00
End date and time of board meeting		29-07-2025 19:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification		Not applicable

Financial Results – Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025	01-04-2025
Date of end of reporting period		30-06-2025	30-06-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	1071.15	1071.15
	Other income	26.52	26.52
	Total income	1097.67	1097.67
2	Expenses
(a)	Cost of materials consumed	545.83	545.83
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	284.31	284.31
(d)	Employee benefit expense	12.56	12.56
(e)	Finance costs	4.82	4.82
(f)	Depreciation, depletion and amortisation expense	25.37	25.37
(g)	Other Expenses
1	Other Expenses	77.33	77.33
	Total other expenses	77.33	77.33
	Total expenses	950.22	950.22
3	Total profit before exceptional items and tax	147.45	147.45
4	Exceptional items	0	0
5	Total profit before tax	147.45	147.45
6	Tax expense
7	Current tax	29.99	29.99
8	Deferred tax	6.78	6.78
9	Total tax expenses	36.77	36.77
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	110.68	110.68
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	1.06	1.06
16	Total profit (loss) for period	111.74	111.74
17	Other comprehensive income net of taxes	0	0
18	Total Comprehensive Income for the period	111.74	111.74
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent	91.42	91.42
	Total profit or loss, attributable to non-controlling interests	20.31	20.31
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
21	Details of equity share capital
	Paid-up equity share capital	1376.27	1376.27
	Face value of equity share capital	10	10
22	Reserves excluding revaluation reserve
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	0.66	0.66
	Diluted earnings (loss) per share from continuing operations	0.66	0.66
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
iii	Earnings per equity share (for continuing and discontinued operations)
	Basic earnings (loss) per share from continuing and discontinued operations	0.66	0.66
	Diluted earnings (loss) per share from continuing and discontinued operations	0.66	0.66
24	Debt equity ratio			Textual Information( 1)
25	Debt service coverage ratio			Textual Information( 2)
26	Interest service coverage ratio			Textual Information( 3)
27	Disclosure of notes on financial results	Textual Information(4)

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025	01-04-2025
Date of end of reporting period		30-06-2025	30-06-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
1	Specialty & Fine Chemicals	840.22	840.22
2	Logistics Business	230.93	230.93
	Total Segment Revenue	1071.15	1071.15
	Less: Inter segment revenue
	Revenue from operations	1071.15	1071.15
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
1	Specialty & Fine Chemicals	44.42	44.42
2	Logistics Business	29.73	29.73
	Total Profit before tax	74.15	74.15
	i. Finance cost	4.82	4.82
	ii. Other Unallocable Expenditure net off Unallocable income	-79.17	-79.17
	Profit before tax	148.5	148.5
3	(Segment Asset - Segment Liabilities)
	Segment Asset
1	Specialty & Fine Chemicals	3781.52	3781.52
2	Logistics Business	1073.79	1073.79
	Total Segment Asset	4855.31	4855.31
	Un-allocable Assets	1567.19	1567.19
	Net Segment Asset	6422.5	6422.5
4	Segment Liabilities
	Segment Liabilities
1	Specialty & Fine Chemicals	435.79	435.79
2	Logistics Business	154.64	154.64
	Total Segment Liabilities	590.43	590.43
	Un-allocable Liabilities	0	0
	Net Segment Liabilities	590.43	590.43
	Disclosure of notes on segments

Other Comprehensive Income
Date of start of reporting period		01-04-2025	01-04-2025
Date of end of reporting period		30-06-2025	30-06-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
	Total Amount of items that will not be reclassified to profit and loss
2	Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00
3	Amount of items that will be reclassified to profit and loss
	Total Amount of items that will be reclassified to profit and loss
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income	0.00	0.00

General information about company

Financial Results – Ind-AS

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Other Comprehensive Income